Figures & data
Figure 1 Injection sites: A, procerus muscle; B, right medial corrugator muscle; C, left medial corrugator muscle; D, right lateral corrugator muscle; E, left lateral corrugator muscle.
![Figure 1 Injection sites: A, procerus muscle; B, right medial corrugator muscle; C, left medial corrugator muscle; D, right lateral corrugator muscle; E, left lateral corrugator muscle.](/cms/asset/74545780-a1df-4b3e-9722-db5ceca9bf57/dcia_a_34854_f0001_c.jpg)
Table 1 Patient demographics
Figure 2 Percentage of responders over time (A) when a responder was defined as a patient with at least a 1-point improvement from baseline at rest and at maximum frown; (B) when a responder was defined as a patient with at least a 2-point improvement from baseline at maximum frown.
![Figure 2 Percentage of responders over time (A) when a responder was defined as a patient with at least a 1-point improvement from baseline at rest and at maximum frown; (B) when a responder was defined as a patient with at least a 2-point improvement from baseline at maximum frown.](/cms/asset/4f1f1daa-c947-4910-8d8e-a552e36ec22a/dcia_a_34854_f0002_b.jpg)
Figure 3 Mean change from baseline glabellar frown lines score on the 5-point scale at maximum frown over time.
![Figure 3 Mean change from baseline glabellar frown lines score on the 5-point scale at maximum frown over time.](/cms/asset/0134b988-3e8f-4984-be61-dc7e491a782f/dcia_a_34854_f0003_b.jpg)
Table 2 Percentage of patients who assessed themselves as having “improved” or “markedly improved” glabellar frown lines compared with baseline
Table 3 Patient questionnaire responses: mean percentage of patients who agreed with the statements at the time points shown